InflaRx (IFRX) Net Margin Growth (3y) (2021 - 2026)
InflaRx (IFRX) Net Margin Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -374.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -44.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -389.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -13,815.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7,793.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 9,934.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -11,156.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,387.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -5,319.00 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.37 Mn |
| Dec 31, 2025 | -676,782.00 |
| Sep 30, 2025 | -5.26 Mn |
| Jun 30, 2025 | -3.66 Mn |
| Mar 31, 2025 | -2.46 Mn |
| Dec 31, 2024 | -60.88 Mn |
| Sep 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | -21.79 Mn |
| Mar 31, 2024 | -2.69 Mn |
| Dec 31, 2023 | -30.24 Mn |
| Sep 30, 2023 | 214,912.00 |
| Jun 30, 2023 | -116,256.00 |
| Mar 31, 2023 | -22.50 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 226,249.00 |
| Jun 30, 2022 | 19,211.00 |
| Mar 31, 2022 | 765,611.00 |
| Dec 31, 2021 | -1.07 Mn |
| Sep 30, 2021 | 139,912.00 |
| Jun 30, 2021 | 7,642.00 |